NCT03315533 - Altering The Transition From Acute to Chronic Pain (ATTAC-Pain) | Biotech Hunter

Enrollment

76

Participants

Timeline

Start Date

January 19, 2018

Primary Completion Date

March 25, 2019

Study Completion Date

April 1, 2019

Conditions

Musculoskeletal Pain

Interventions

DRUG

Duloxetine 30 milligrams (MG)

Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo

DRUG

Duloxetine 60 milligrams (MG)

Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo

DRUG

Placebo Oral Tablet

Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo

Trial Locations (1)

02903

Rhode Island Hospital, Providence